JAK1 pathway inhibitors for the treatment of prurigo nodularis

A method for treating prurigo nodularis in a subject, said method comprising administering to the subject a therapeutically effective amount of JAK1 pathway inhibitor 4-[3-(cyanomethyl)-3-(3′,5′-dimethyl-1H,1′H-4,4′-bipyrazol-1-yl)azetidin-1-yl]-2,5-difluoro-N-[(1S)-2,2,2-trifluoro-1-methylethyl]benzamide, or a pharmaceutically acceptable salt thereof, to a subject in need thereof.